Key Takeaways
- Novartis’s decision to discontinue development of pelacarsen, an antisense oligonucleotide targeting Lp(a), has shifted investor focus towards alternative cardiovascular drug development pathways.
- Investments are now concentrating on gene-editing technologies like CRISPR and base editing for long-term Lp(a) reduction, with companies like Verve Therapeutics showing promise in early trials.
- The regulatory pathway for novel gene therapies in cardiovascular disease remains a key consideration, demanding strong safety data and clear efficacy markers for investor confidence.
- Small molecule inhibitors and RNA interference (RNAi) therapies for Lp(a) reduction continue to attract venture capital, offering potentially broader patient accessibility and different administration routes.
- Biotech firms with diverse cardiovascular pipelines, not solely reliant on Lp(a) modulation, are seen as more resilient to single-asset setbacks, attracting sustained investor interest in 2026.
Novartis announced in early 2026 the discontinuation of its investigational Lp(a)-lowering drug, pelacarsen, following a strategic portfolio review, sending ripples through the biotech investment community. This move, impacting a highly anticipated cardiovascular drug development candidate, forces a recalibration of investor outlooks on next-generation therapies for atherosclerotic cardiovascular disease (ASCVD). The question now for venture capitalists and pharmaceutical giants alike is: where does the smart money flow in a post-pelacarsen field?
Context and Background
Pelacarsen, an antisense oligonucleotide developed in partnership with Ionis Pharmaceuticals, aimed to reduce lipoprotein(a) or Lp(a), a genetic risk factor for heart disease that affects millions globally. Its progression through clinical trials, including the large-scale HORIZON study, had been closely watched as a potential breakthrough. However, despite promising early-stage data, Novartis’s decision shows the inherent risks in late-stage drug development, particularly for novel mechanisms. This isn’t an isolated incident. The pharmaceutical industry consistently faces high attrition rates for drug candidates, even those targeting well-understood biological pathways. The challenge with Lp(a) has always been its complex genetic regulation and the need for durable, significant reductions without off-target effects.
Implications for Biotech Investment
The void left by pelacarsen’s exit has intensified focus on other innovative approaches to Lp(a) reduction and broader cardiovascular health. We’re seeing a clear pivot towards gene-editing technologies and RNA interference (RNAi). Companies like Verve Therapeutics, with their CRISPR-based gene editing candidate targeting PCSK9 and ANGPTL3 for hypercholesterolemia, are gaining significant traction. While not directly Lp(a)-focused, their platform demonstrates the potential for durable, single-dose interventions that could eventually be adapted for Lp(a). According to a recent report by Evaluate Pharma, venture capital funding for gene therapy startups in cardiology increased by 15% in the first quarter of 2026 compared to the previous year, indicating strong investor confidence in these high-risk, high-reward modalities. Plus, attention is shifting to companies developing small molecule inhibitors that indirectly impact Lp(a) synthesis or catabolism, as well as other RNAi therapies. For example, Amgen’s olpasiran, another Lp(a)-targeting RNAi therapy, continues its clinical development, offering a different mechanistic approach. These alternatives present varying risk profiles and market opportunities. Investors are now scrutinizing not just the efficacy data, but also the potential for scalability, manufacturing complexity, and long-term safety profiles of these novel therapies. My own assessment, based on discussions with biotech fund managers, is that diversification within a cardiovascular portfolio is more critical than ever. Betting on a single mechanism, however promising, carries substantial risk.
What’s Next for Cardiovascular Drug Development?
The road ahead for cardiovascular drugs is paved with both challenges and opportunities. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are still refining guidelines for gene-editing therapies, particularly regarding long-term safety monitoring. This regulatory uncertainty can impact investor timelines and expected returns. However, the unmet medical need for Lp(a)-driven ASCVD remains substantial, creating a powerful incentive for continued innovation. I anticipate a surge in early-stage investment in platforms that offer multiplex gene editing or novel delivery systems for RNA-based therapies. The ability to precisely target specific genes with minimal off-target effects will be a key differentiator. Plus, companies that can demonstrate clear pathways to patient identification (through advanced diagnostics for Lp(a) levels, for instance) and patient access will likely attract premium valuations. We might also see increased strategic partnerships between large pharmaceutical companies and smaller biotech firms specializing in these advanced modalities, as larger players seek to de-risk their pipelines. The pelacarsen news, while a setback for one drug, in the end accelerates the broader push towards truly far-reaching therapies in cardiovascular medicine. The discontinuation of pelacarsen shows the inherent volatility of drug development but also highlights the resilience and adaptability of biotech investment. Focus has now sharpened on gene-editing and RNAi platforms, demanding strong safety and efficacy data for investor confidence. Companies that can demonstrate a clear path to market with differentiated, durable solutions will secure the next wave of capital in the evolving cardiovascular therapeutic space.
What is Lp(a) and why is it a target for drug development?
Lipoprotein(a), or Lp(a), is a type of low-density lipoprotein (LDL) that is genetically determined and acts as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), including heart attacks and strokes. It’s a significant target because current standard therapies like statins do not effectively lower Lp(a) levels, leaving a large population at elevated risk.
How does gene editing aim to reduce Lp(a) levels?
Gene editing technologies, such as CRISPR, aim to permanently alter the genetic instructions within liver cells that produce Lp(a). By precisely modifying or silencing the gene responsible for Lp(a) synthesis, these therapies seek to achieve a durable and significant reduction in Lp(a) levels with potentially a single treatment.
What are the main alternatives to antisense oligonucleotides for Lp(a) reduction?
Beyond antisense oligonucleotides, the primary alternative approaches for Lp(a) reduction include RNA interference (RNAi) therapies, which block the production of Lp(a) protein, and gene-editing technologies, which aim for permanent genetic modification. Some research also explores small molecule inhibitors that may indirectly impact Lp(a) metabolism.
What factors are investors now considering most critically in cardiovascular biotech?
Investors are now critically evaluating the durability and magnitude of Lp(a) reduction, the long-term safety profile of novel therapies (especially gene-editing), the scalability of manufacturing, and the clarity of regulatory pathways. Diversification within a biotech portfolio, moving beyond single-asset bets, is also a key consideration.
How might the regulatory field evolve for gene therapies in cardiovascular disease?
Regulatory bodies are likely to demand extensive long-term safety data for gene therapies, particularly concerning off-target effects and potential immunogenicity. There may be an emphasis on real-world evidence collection post-approval, and adaptive trial designs could become more common to accelerate development while gathering complete safety information.
